

Apellis to participate in a webcast on innovating for ophthalmic diseases

Crestwood, KY— October 7, 2016 — Cedric Francois, MD, PhD, Co-founder & CEO/President of Apellis Pharmaceuticals, Inc. will participate in a BioPharma Dealmakers webcast, sponsored in part by Apellis, featuring three companies innovating in therapies for eye disorders. The webcast, part of the BioPharma Dealmakers series, is scheduled for 10:00 am ET on October 20th.



[> Webcast registration link](#)

This webcast will explore some of the latest advances in the ophthalmic field through discussion with representatives from companies developing a range of innovative therapies for eye disorders, including the use of iPS cells, eye drops to deliver small-molecule drugs and complement inhibition.

The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to participate and put your own questions to the speakers.

Cedric Francois received his MD from the University of Leuven in Belgium and his PhD in physiology from the University of Louisville. Prior to co-founding Apellis, he co-founded Potentia Pharmaceuticals, Inc., a private biotechnology company where he has served as President and Chief Executive Officer since 2001.

Other webcast participants include:

- **Hardy TS Kagimoto, MD**, President, Representative Director and CEO of HEALIOS K.K.
- **Dr. George Nikopoulos**, CEO & President of Mannin Research Inc.
- **Moderator: Raveena Bhambra**, Editor of *BioPharma Dealmakers*. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.

About the Webcast

[BioPharma Dealmakers webcasts](#) are dedicated to small and large companies looking for commercial partnerships. Read the quarterly [BioPharma Dealmakers supplement](#) in *Nature Biotechnology* and *Nature Reviews Drug Discovery*.

About Apellis

Apellis is a clinical stage biopharmaceutical company focused on the development of a platform of novel therapeutic compounds for the treatment of a broad range of autoimmune diseases based upon complement immunotherapy. Apellis is currently evaluating its lead product candidates in Phase I and Phase II clinical trials in paroxysmal nocturnal hemoglobinuria (PNH), geographic atrophy in age-related macular degeneration (AMD), and chronic obstructive pulmonary disease (COPD). For additional information about the company, please visit www.apellis.com

Contact:

David Watson, General Counsel, Apellis Pharmaceuticals, Inc., davidw@apellis.com

###